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31.1 INTRODUCTION
The administration of a bioactive factor aims to obtain a specific therapeutic response
at the anatomical target, without leading to the appearance of undesirable side-effects.
In conventional therapies, drugs are administered freely, and consequently may be
distributed arbitrarily through the body, reaching tissues where a pharmacological
response is not observed, but could be responsible by the appearance of toxic effects.
In fact, some drugs administered via conventional pharmaceutical formulations have
been withdrawn from the market, due to their unexpected toxic effects in nontarget
tissues [1, 2]. This can be overcome, or at least reduced, by the entrapment of the
therapeutic agent in delivery systems. With delivery systems, the pharmacokinetics
and pharmacodynamics of a drug can be enhanced, increasing its therapeutic index
[3] Additionally, delivery systems offer other advantages such as protection of the
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entrapped material against degradation by, for example, light or enzymes, incorpora-
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tion of both hydrophilic and hydrophobic compounds, and they make possible drug
targeting with controlled release [3–5]. Indeed, delivery systems can be used to carry
not only synthetic molecules, but also peptides, proteins and nucleic acids whose
protection from degradation is crucial.
Besides the conduct of the pharmaceutical compound at the site of action, other
essential functions thatmust be provided by these carriers is to release them at concen-
trations lying within the therapeutic range during a certain period of time (Fig. 31.1)
[6]. The possibility of drug targeting can thus decrease the dose required to observe
the therapeutic response and avoid side-effects. From Figure 31.1 it is possible to
observe that drug blood concentrations higher than the minimum toxic concentra-
tion (MTC) present a toxic risk for patients. On the other hand, concentrations below
the minimum effective concentration (MEC) lead to drug quantities insufficient to
treat the disease. In this sense, the devices must be designed to achieve therapeuti-
cally relevant concentrations through controlled release. This leads to reduced dos-
ing frequency, culminating with a greater patient acceptance and compliance, thereby
improving human health [7]. Taking into account that the main aim of a delivery sys-
tem is to release a defined therapeutic agent at a controlled rate, the mechanisms that
contribute to this will be addressed within this chapter.
As derivatives of extracellular matrix components, natural-origin polymers can
function not only as bioactive factor delivery systems and DNA complexing agents,
but also as structural scaffolds for tissue engineering applications [8]. Typically, the
bioactive factors are incorporated within the internal structure of biomaterials dur-
ing the processing steps or are otherwise bonded or adsorbed at the surfaces of the
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FIGURE 31.1 Drug concentration along time for a conventional formulation administered
at pre-defined time intervals (↑) and for delivery devices with or without controlled release,
showing the therapeutic range and the minimum toxic concentration (MTC) and the minimum
effective concentration (MEC). Adapted from Liechty et al. [6].
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structured biomaterials, depending on the actions of the therapeutics and the target
cells/tissues. While the former is more relevant to gain long-term therapeutic effects
in a more sustainable and time-dependent manner, the latter mainly targets direct
actions with the contacting cells. Depending on the paths of action and roles of the
bioactive factors, the design of delivery matrices and vehicles should be carefully
considered, either targeting binding to cell membrane receptors (growth factors), pen-
etration into cell membrane (drugs or genes) or even transport to nuclear pores for
direct genetic modification (genes). Therefore, this chapter will discuss the current
status on the use of natural polymers for drug, protein and gene delivery, with a spe-
cial focus on research with applications in tissue engineering.
31.2 ADVANTAGES AND DISADVANTAGES OF NATURAL
POLYMERS-BASED DELIVERY SYSTEMS
Although the majority of the delivery systems are based on synthetic polymers,
natural-origin polymers have the advantage of having the intrinsic property of
environmental responsiveness via degradation and remodeling by hydrolysis or cell-
secreted enzymes (Table 31.1). They are generally nontoxic, mucoadhesive, biocom-
patible and biodegradable, and therefore can readily be incorporated into oral delivery
or bulk matrix delivery systems. Additionally, the typical biodegradability of the
natural polymers present an advantage in terms of originating nontoxic compounds
that can be eliminated by normal clearance processes of the body. The crosslinking
of natural polymers in nontoxic ways, such as using agents with reduced toxicity
(e.g. N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and
N-hydroxysuccinimide (NHS), dehydrothermal treatment), and forming interpene-
trating networks has, thus, been pursued for achieving structural integrity of the host
scaffolds and the sustainable release of incorporated bioactive factors [9–12].
TABLE 31.1 Advantages and disadvantages of natural polymers-based delivery
systems
Advantages Disadvantages
 Readily available from natural sources
 Biodegradability
 Biocompatibility
 Hydrophilicity
 Availability of functional groups for
drug immobilization
 Presence of biologically recognizable
moieties that support cellular activities
 Faster drug release
 Shorter biodegradability
 Necessity of crosslinking for stability in
physiological conditions
 May evoke immune/inflammatory responses
 Difficult to isolate natural polymers with high
purity and at industrial scale amounts
 Batch to batch variation
 May contain pathogens from other species
 Regulatory issues for commercial approval
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The most common scaffolds used to incorporate bioactive factors are polymers,
and the bioactive factors have been incorporated either during the process of the scaf-
folds or after their fabrication. The incorporation of bioactive factors within scaf-
folds needs careful consideration to maintain the bioactivity of the factors and conse-
quently to potentiate their therapeutic effects. Although synthetic biopolymers have
shown better mechanical properties than natural ones when processed by solvent-
based techniques, the organic solvents used to dissolve the synthetic polymers are
not readily available for the use of bioactive factors. Because most bioactive factors
require water-based solutions, natural biopolymers are preferred over synthetic ones.
Therefore, the sequestering of bioactive factors within natural polymers formulated
in nanostructures helps avoid the harsh processing conditions of most synthetic poly-
mers. Furthermore, in synthetic-origin delivery systems the hydrophilic bioactive fac-
tors are segregated and not homogenously distributed within the synthetic matrices.
Many natural polymers including collagen, gelatin and chitosan, have charged func-
tional groups and present a more or less ionic affinity to therapeutic biomolecules
such as growth factors [13].
From the current research, there appear to be hints that natural polymeric carriers
have a different mechanism for intracellular escape and transfection than their syn-
thetic polymer counterparts. These differences can be at the cell surface level, the
endosome release level, nuclear transport level, or any other potential rate-limiting
steps [14]. Polymer molecular weight, charge density, as well as the possibility
to change the overall drug or gene/polymer surface charge, surface ligands, and
enhancement of availability near the cell surface are some of the factors that can
be optimized to improve transfection efficiency of any given carrier [15]. System-
atic studies varying these degrees of freedom should provide significant insight into
development of natural polymers for use in gene therapy and tissue engineering [16].
31.3 FUNDAMENTALS OF DRUG DELIVERY
The entrapment or chemical conjugation of a therapeutic agent with a polymer for
the treatment of a wide variety of diseases have received much attention over the past
decades. Due to the advantages presented by natural polymers (Table 31.1), they have
been continuously investigated to develop innovative and more effective and special-
ized release dosage forms. For example, insulin and pectin can be used to achieve a
colon-specific drug delivery and using alginate is possible to obtain a gastro-retentive
formulation [17]. Therefore, the selection of the most adequate biodegradable poly-
mer is crucial to obtain systems with the desired properties of drug release. The lower
or higher rate of polymer biodegradation in the biological fluids will result in a slower
or faster release of the drugs dissolved or dispersed in the selected delivery system.
At the same time, the drug release profile can also be influenced by the delivery sys-
tem preparation method whose choice depends, for example, on the nature of the
therapeutic agent and on the selected delivery route [18].
Numerous efforts have been made to design delivery systems that allow releasing
of the bioactive agents in a predictable and controlled manner, when administered
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by oral, topical, rectal, intravenous or other route. Independently of the delivery sys-
tem geometry, the most usually required release profile is a uniform drug concen-
tration within a therapeutic range over a considerable period of time (Fig. 31.1).
However, in recent years, efforts have been made to achieve a release of the ther-
apeutic agent in a pulsatile fashion, triggered by changes in the surrounding environ-
ment or by an external stimulus [6, 19]. Due to the relevance of the various mecha-
nisms behind the drug release profile, mathematical models have been developed to
describe it [20–28]. In fact, the existence of a mathematical model that can predict the
exact drug release mechanism and, consequently, the concentrations that are obtained
in vivo during the delivery system ‘half-life’ would be an asset in the development
of new pharmaceutical formulations. Nevertheless, in vitro release studies are always
useful to predict and to provide a basis for the in vivo release profile, despite the
fact that a direct correlation between in vitro and in vivo behavior cannot always be
achieved [29].
Typically, the polymeric pharmaceutical delivery systems can be divided into five
categories according to the mechanism that control the release of the therapeutic
agent: diffusion controlled systems, chemically controlled systems, solvent-activated
systems, externally triggered systems and self-regulated delivery systems (Fig. 31.2)
[6, 19, 30, 31]. Notwithstanding, a delivery system can present not only one of these
mechanisms, but can actually involve two or more mechanisms. For instance, a study
in which bovine serum albumin (BSA) and human serum albumin (HAS) micro-
spheres were used to carry piroxicam showed that the nonsteroidal anti-inflammatory
release was conducted by drug diffusion and polymer chain degradation [32].
31.3.1 Diffusion Controlled Systems
The diffusion controlled systems can be monolithic (matrix) or reservoir systems
(Fig. 31.2a and 2b) [6, 33]. In monolithic systems, the drug dissolved or dispersed
in the matrix is released by diffusion. Therefore, these systems maintain their struc-
ture and do not suffer alterations by swelling, degradation or erosion. The drug can be
released through pores present in the particles structure [27] or can be conducted sim-
ply by the drug passage through the polymer chains [33]. In the monolithic systems,
the distribution of the drug must be, ideally, uniform through the polymer matrix [33].
Usually, faster releases occur for molecules closer to the particle surface and, as they
become further embedded in the particle, the release velocity decreases. On the other
hand, it is possible to obtain a desired release rate by including the therapeutic agents
in the system core surrounded by a uniform polymeric layer that controls the diffu-
sion rate [24, 33]. As for monolithic systems, the diffusion of the drug through the
polymer in the reservoir diffusion controlled systems is the rate-limiting step [33].
The release rate in this type of system is time-independent (zero order) for planar,
cylindrical or spherical systems in geometry [24]. In fact, the geometry of the system
constitutes a factor that can control the drug release rate, as well as the membrane
thickness, the drug concentration across the membrane, the system thermodynamic
properties via the partition coefficient and the polymer structure through the solute
diffusion coefficient.
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FIGURE 31.2 Illustration of diffusion controlled systems (a; b), chemically controlled sys-
tems (c; d), solvent activated systems (e) and externally-triggered/self-regulated systems (f).
31.3.2 Chemically Controlled Systems
The chemically controlled systems encompass biodegradable and bioerodible carri-
ers, as well as the systems in which the drug is linked to the polymer (Figure 31.2c and
d) [6, 24]. Biodegradable polymers suffer degradation to smaller compounds when
incorporated into physiological conditions and, contrariwise, with the erodible poly-
mers did not experience a chemical modification of their structure, but their dissolu-
tion. Consequently, in these systems the higher or lesser degradation or dissolution
of the polymer chains will influence the bioactive factors release rate [24].
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For systems having the drug linked to the polymer, the drug release will be con-
trolled by the velocity at which the drug–polymer bonds are cleaved, either enzymat-
ically or hydrolytically [24]. The link of the drug to the polymer may or may notAU: ‘may or
may not’:
correct as copy
edited? If not
please clarify.
be performed via a spacer group, which can also affect the drug release rate and the
hydrophilicity of the system [33].
31.3.3 Solvent-Activated Systems
Solvent-activated systems are vehicles that swell when in contact with physiological
fluids, increasing their volume and allowing drug diffusion to the surrounding media
(Fig. 31.2e) [6, 25, 33, 34]. Therefore, the drug release depends on the ability of the
biological fluids to penetrate the polymeric delivery system [22, 25, 35]. The release
profile of these systems and of bioerodible carriers are similar, if the surface erosion
in the bioerodible is the unique factor responsible for the release of a drug [33]. These
systems are based in hydrogels, which can absorb a considerable quantity of water or
physiological fluids. In systems not chemically crosslinked, the dissolution creates
an erosion front, besides diffusion and swelling [6]. During swelling, the solvent-
activated systems go from the glassy state to the rubbery state, this last state being the
one that allows the drug release [24]. Consequently the systems present two phases
until all systems stay in the rubbery state. The velocity and position of the glassy–
rubbery interface will determine the drug release rate [24].
31.3.4 Externally Triggered Systems
The externally triggered systems are devices in which the drug is released due
to an external stimulus, as magnetic, ultrasonic, thermal, electric and irradiation
(Fig. 31.2f) [19]. In magnetically triggered systems, the polymer matrix is enriched
with magnetic beads together with the therapeutic agents [36, 37]. For example,
a study performed with alginate spheres containing insulin and magnetic particles
showed that the release rate of the protein was much higher (around 50 times higher)
when the magnetic field was applied [37]. The same study also demonstrated that
when alginate spheres were crosslinked, the released of insulin was also higher than
in the absence of the magnetic field. However, this effect did not occur immediately,
but it happened only after applying the oscillating magnetic field. In this perspec-
tive, it is possible to conclude that the release rate in these systems also depends on
mechanical properties of the polymeric device. Additionally, this event depends on
the position, orientation and magnetic strength of the magnets and on the amplitude
and frequency of the magnetic field applied [19].
31.3.5 Self-Regulated Delivery Systems
In self-regulated delivery systems the release rate is adjusted in response to the evolu-
tion of the illness or the physiological need (Fig. 31.2f) [19,31]. Several mechanisms
can be used to modulated the feed-back action of drug delivery systems: pH-sensitive
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polymers, enzymes, illness markers, pH-dependent drug solubility, competitive bind-
ing and metal concentration-dependent hydrolysis [19]. For example, a design of
this closed-loop controlled system consists of immobilizing urease to the polymeric
vehicle [38]. This enzyme converts urea to ammonium bicarbonate and ammonium
hydroxide, thereby increasing the pH, that can leads to a higher erosion or swelling
of the polymer that enhances the drug release [39]. The solvent activated systems
mentioned before become even more attractive when the swelling is controlled by
an internal stimulus that can be a change in pH, temperature, solvent composition
or ionic strength in the environmental surroundings [34, 40]. In this approach, these
systems will only release the entrapped material at specific sites, where and when
the environmental aspect for which they are sensitive is present. For instance, pH-
sensitive polymers that swell at low pH, as observed in inflammatory processes, will
only release the entrapped material in anatomic/cell locations characterized by this
physiological condition. The swelling at low pH is also attractive, for example, when
it is necessary to obtain a localized delivery at the stomach to treat an infection caused
by Helicobacter pylori [41]. The polymers used to swell at low pH are polybasic in
nature, such as chitosan [42], unlike the polyacid polymers which will shrunk at low
pH, but swells with the increasing pH, like carboxymethylcellulose [19,39]. pH stim-
ulus is generally associated with a change in body conditions such as at the site of
tissue and organ or intracellular compartments. Common examples are found in the
fields of gastrointestinal tract, changes in blood stream pH, or tissues in a patho-
logical situation such as clot or cancer. Therefore, biomaterials for such fields have
mainly been developed as nano/microparticulate carriers that allow oral uptake or
intravenous injection. The responsiveness of candidate biomaterials to pH is accom-
panied mainly by a change in size/shape (swell/shrink or collapse), thereby allowing
the release of certain drugs from the interior [43]. Some natural polymers like chi-
tosan, alginate, and gelatin andmany synthetic polymers have been developed for this
purpose. Protein release from alginate, chitosan, and pectin microparticles analyzed
at different pH simulating gastric (pH 1.2 and 5.0), intestinal (pH 7.4) and colonic
(pH 6.0 and 6.8) activity is highly pH dependent; release is sustained at gastric pH
but increased at intestinal and colonic pHs [44].
pH-sensitive polymers can also be used linked to an enzyme whose reaction prod-
uct alters the pH of the surrounding media, as the urease mentioned before [38],
and consequently the release rate is adjusted by the presence of a specific com-
pound in the system. Another approach that can be used is to proceed to the immo-
bilization of glucose oxidase to the devices for controlled release of insulin [28, 45].
This enzyme converts glucose into gluconic acid, which leads to a decrease of the
pH within the system and as a result gel swelling occurs. In this way, as required,
insulin delivery is controlled by glucose concentrations. In fact, pH-sensitive poly-
mers are usually loaded with enzymes whose product of reaction leads to an alter-
ation of the pH in the local microenvironment, being glucose oxidase commonly
used for this purpose [40]. Another delivery system composed of 6-mercaptopurine-
carboxymethyl chitosan showed a release rate pH-sensitive and dependent on the
glutathione presence [46]. As this is a reducing agent at a higher concentration in
the cells, these devices were developed to provide an intracellular controlled release.
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In another work, poly(ethylene glycol) (PEG)-modified thiolated gelatin nanoparti-
cles were used to take advantage of intracellular glutathione concentrations for DNA
delivery [47]. The authors showed that the delivery systems developed were able to
transfect cells in vitro to a greater extent than Lipofectin-plasmid DNA complexes.
31.4 IN VITRO AND IN VIVO APPLICATIONS OF NATURAL-BASED
DELIVERY SYSTEMS
Natural polymer-based delivery systems such as micro- or nano-particles, gels, mem-
branes, sponges and scaffolds have been broadly proposed for drug administration,
targeting and delivery. Besides targetting and delivery in a certain tissue or cell, efforts
have been made to intracellularly carry and/or to release in response to physiological
needs. Natural polymers can be mixed with other compounds or chemically modified
to improve their properties for the development of innovative drug delivery systems.
Additionally, functionalized delivery systems of hybrid, composites and grafted poly-
mers can strengthen the responsiveness to a wide range of external or internal stimulii,
as previously mentioned.
A biodegradable, porous carrier system is convenient for the clinician, as it lim-
its and protects the release of drugs, proteins or genes in a predictable and time-
controlled manner. Simultaneously, these delivery systems should allow cell growth
and act transiently as an extracellular matrix until sufficient cells are present to build
a new substratum.
31.4.1 Drug Delivery Systems
There are numerous works in the literature that evidence the value of natural poly-
mers in the formulation of spatiotemporal controlled drug delivery systems. Chi-
tosan, for instance, is a polymer usually used as drug delivery carrier, since it shows
antibacterial activity [48,49] and the ability to accelerate wound closure and healing
[50], thereby being an attractive wound dressing device. The use of chitosan sponges
incorporating the antibiotic norfloxacin as wound or burn dressings [51] is an exam-
ple which uses the intrinsic therapeutic properties of the device. In another study,
starch-conjugated chitosan microparticles incorporating gentamicin presented a sus-
tained release of the antibiotic in effective concentrations that exert its antibacterial
activity and consequently has potential to treat bone infections, as suggested by the
authors [52]. In another attempt, carboxymethyl-chitosan grafted onto low generation
poly(amidoamine) (PAMAM) dendrimers and carrying dexamethasone demonstrated
the ability to induce osteogenic differentiation of rat bone marrow stem cells in vitro
[53]. This glucocorticoid and mouse lung fibroblastic cells were also encapsulated
into chitosan-based spherical particles as a two-in-one tissue engineering construct
[54]. These systems showed pH-sensitive behavior and the ability of drug sustained
release, preserving encapsulated cells viability.
The pH-responsive delivery was also demonstrated in devices of carboxylmethyl-
chitosan grafted with phosphatidylethanolamine incorporating the hydrophobic drug
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ketoprofen [55]. This study demonstrated that, in the presence of an acidic medium, a
higher release of the drug occurred. A pH-sensitive hydrogel made of a blend of chi-
tosanwith polyvinyl pyrrolidone (PVP)was developed to obtain a selective controlled
release of the antibiotic amoxicillin in the acidic pH of the stomach [56]. In fact, chi-
tosan has a limited utilization for oral formulations, since it solubilizes at the stomach,
leading to a fast release of the incorporated drugs. On the other hand, it is also pos-
sible to obtain particles that did not disintegrate at the stomach by the surrounding
environment, by developing a system composed by a chitosan core with a hydropho-
bic cellulosic shell [57]. This system presents the ability to modulate the in vitro
release profile of sodium diclofenac and fluorescein isothiocyanate-labeled BSA.
It was also described in the literature that chitosan shows tumor growth inhibitory
activity [58]. An example relates to the local administration of a photo crosslink-
able chitosan hydrogel (with azide and lactose moieties) containing paclitaxel [58].
This study showed that the drug delivery system presented a higher inhibitory activ-
ity over angiogenesis and tumor growth in mice, than the chitosan hydrogel or the
paclitaxel alone. Pectin-coated chitosan hydrogel used to incorporate 5-fluorouracil
also demonstrated a pH-dependent release, which was slower at acidic pH and higher
at neutral pH, supporting the anticancer therapeutic action of the drug and therefore
can be used, as suggested, for the treatment of colon tumors [59]. The mucoadhe-
sive property of chitosan was also explored in bladder cancer treatment to obtain the
desired attachment of the mytomycin-C delivery system to the bladder wall [60]. Tis-
sue engineering scaffolds can also be made of chitosan by the use of green processing
technology (i.e. supercritical fluids), which show the ability for the sustainable release
of dexamethasone [61].
Besides chitosan, other natural polymers showed a great potential in drug con-
trolled release. Hyaluronic acid-based hydrogels demonstrated the potential for slow
and sustained release of hydrophobic anti-inflammatory steroids [62]. A mixture of
hyaluronic acid and chitosan allows the production of a temperature sensitive hydro-
gel, first prepared by Fang et al. [63]. This study demonstrated, in vivo, that the devel-
oped system showed the ability of nalbuphine-controlled release, leading simultane-
ously to an increase duration of its analgesic effect.
Gellatin nanoparticles were also used to incorporate and to sustain release of the
anticancer drug 5-fluorouracil [64]. Starch-based porous materials also demonstrated
the ability for the controlled release of meclofenamic sodium salt, a nonsteroidal
anti-inflammatory drug [65]. Gellatin and HSA nanoparticles functionalized with
HER-2 (human epidermal growth factor receptor-2) specific antibody trastuzumab
(Herceptin®) were used to drug target tumor cells [66]. This study demonstrated the
effectiveness and specificity of the protein nanoparticles to bind and be internalized
in HER-2-overexpressing cancer cells.
Crosslinked oxidized alginate hydrogels were considered to locally deliver three
anticancer drugs, namely methotrexate, doxorubicin and mitoxantrone [67]. While
methotrexate was localized into the hydrogel pores, the doxorubicin and mitox-
antrone were covalently bound and ionically complexed, respectively, to the polymer.
These hydrogels can, therefore, be used to deliver one or more therapeutic agents,
by different controlled-release mechanisms. Under a magnetic field, curcumin, an
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anticancer drug, was released in a higher rate when administered in a magnetic
hydrogel of gum arabic, chitosan or maltodextrin [49]. A pH- and redox-responsive
alginate-based microcapsule for intracellular degradability and docetaxel delivery
was developed [68]. This delivery system was produced through dynamic covalent
assembly of a Schiff base and disulfide, taking advantage of the redox potential pre-
sented in the intracellular environment.
31.4.2 Protein Delivery Systems
The use of polymeric vehicles to locally deliver growth factors (GFs) in various for-
mats provides a method of controlled, localized delivery for the desired time frame
[35]. Various encapsulation processes utilizing harsh solvents, crosslinking agents
and high temperatures have been used, which could result in the denaturing and deac-
tivation of the incorporated proteins. A variety of processing techniques have been
developed to bypass these issues including soaking the polymeric scaffold in a solu-
tion of a defined growth factor after processing, the use of hydrogel delivery sys-
tems where growth factor incorporation can be achieved at low temperatures [69],
and supercritical carbon dioxide processing [70]. Chemical/genetic modifications
of GFs were also conducted to improve their stability and bioactivity with proved
success.
Collagen, the industry’s favored natural-origin polymer, has been used to cre-
ate various delivery vehicles: collagen sponges, strips, gels, membranes, and oth-
ers [71]. Bone morphogenetic protein (BMP) 2, an osteogenic growth factor, FDA
approved and routinely used in orthotropic sites for bone generation, was absorbed
to collagen sponge and the feasibility of their use in local alveolar ridge preservation/
augmentation [72], in maxillary sinus augmentation [73] and in femoral rat defects
[74] demonstrated. Further on, it has been reported that recombinant human rhBMP-
2 and rhBMP-6 are retained better than rhBMP-4 [75]. In another work, colla-
gen sponges carrying cartilage derived morphogenetic protein 2 (CDMP-2) were
implanted subcutaneously, intramuscularly or inside a freshly created defect in the
achilles tendon of rats [76]. Large amounts of bone were induced subcutaneously,
smaller amounts intramuscularly and, in the tendons, only small amounts of bone or
cartilage were seen in a few animals. Thus, the amount of bone appeared inversely
related to the degree of mechanical environment. A native type I collagen gel aug-
mented with insulin-like growth factor 1 and 2 (IGF-1 and -2) significantly enhance
the osteoconductive repair of nasal critical-size defects in a rodent model [77]. The
results indicate that rat nasal defects treated with IGF-2-augmented collagen gels
showed healing that was significantly greater than the IGF-1 augmentation, the com-
bination of IGF-1 and IGF-2 augmentation, and that of collagen gels-only treatment.
In a similar approach, a porous collagen–glycosaminoglycan scaffold was loaded
with a range of IGF-1 concentrations to evaluate its potential as a controlled delivery
system [11]. The bioactivity of released IGF-1 was confirmed by seeding of the sys-
tems (pre-adsorbed with IGF-1) with human osteoarthritic chondrocytes, demonstrat-
ing an increased proteoglycan production in vitro. The effect of exogenous platelet-
derived growth factor (PDGF) BB on bone healing was also demonstrated using a
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collagen [78] or a composite of chitosan/tricalcium phosphate (TCP) sponge [79] as
carriers, in a tibia defect of rabbits or in a calvarial defect of rats, respectively.
The BMP-2 was also directly immobilized on silk fibroin films, which were able to
induce an enhanced osteogenic differentiation of human bone marrow stromal cells
(hBMSCs) when compared to the ones cultured in the presence of soluble osteogenic
supplementation [80]. Indeed, this permanent immobilization of biomolecules leads
to long-term presentation of bioactive molecules to the seeded cells from the poly-
meric surface. Chondroitin sulphate, which consists of a network of highly negative-
charged groups and is categorized as GAG-like heparin, can improve the binding
ability to BMP-2 and, subsequently, prolonged release when combined into colla-
gen scaffolds [9]. A more recent study highlights the spatiotemporal control of the
regenerative process by utilizing a hybrid growth factor delivery system that consists
of an electrospun nanofiber mesh tube for guiding bone regeneration combined with
peptide-modified alginate hydrogel injected inside the tube which was developed for
the sustained delivery of rhBMP-2 [81]. This system resulted in complete bony bridg-
ing of challenging 8 mm femoral bone defects in a rat model, when compared to the
current clinical standard of collagen delivery.
Fibrin matrices functionalized with heparin were also developed as GFs delivery
systems, consisting of a heparin-binding peptide (HBP) derived from antithrombin
III (ATIII) and a Gln acceptor substrate [82]. The covalent tethering of this linker-
peptide to fibrin matrices during crosslinking confers heparin affinity to the fibrin
matrix. Thus, heparin and GFs with a natural affinity for heparin are preferentially
retained within this modified fibrin matrix leading to a slow and continuous deliv-
ery modality. This strategy was employed for the delivery of a variety of GFs such
as beta-nerve growth factor (β-NGF) [83], neurotrophin-3 (NT-3) [84, 85], FGF-2
[86] or PDGF-BB [87]. In vitro and in vivo data demonstrated the ability of such
heparin-binding GFs systems to promote nerve regeneration, angiogenesis and ten-
don healing. A fibrin gel incorporating transforming growth factor beta (TGFβ) 1
displayed a slow release profile and was, consequently, effective in chondrogenic dif-
ferentiation while suppressing osteogenic differentiation [88]. For skin regeneration,
epidermal growth factor (EGF) fused with the fibrin-binding domain of fibronectin
has reportedly shown higher affinity than the EGF alone to the fibrin matrix, with
the EGF-loaded fibrin promoting the growth of fibroblasts and keratinocytes, and
subsequent wound repair [89]. Since heparin is a widely used anticoagulant, immo-
bilization of heparin on collagen matrices reduces the thrombogenic activity of col-
lagen and may therefore prevent platelet adhesion and blood coagulation. Therefore,
heparin-modified collagen matrices were employed as vascularization scaffolds able
to deliver vascular endothelial growth factor (VEGF) [90] or fibroblast growth factor
(FGF) 2 [91], as well as an in vivo recruitment scaffold of hematopoietic cells using
the stromal cell-derived factor-1 alpha (SDF-1α) [92] or its involvement on the wound
contraction inhibition and re-epithelialization stimulation in a mouse full-thickness
excision skin wound model [93].
Along similar lines, the development of an injectable hyaluronic acid (HA)-based
hydrogel crosslinked with PEG-diacrylate and consisting of thiol-modified heparin
(heparin-DTPH) was reported [94, 95]. This hydrogel network was further modified
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with chondroitin sulphate (CS-DTPH) or thiol-modified gelatin, and has been used to
deliver several proteins, including FGF-2 [96, 97], hepatocyte growth factor (HGF)
for the concomitant recruitment of hBMSCs [98], and combinations of VEGF with
bFGF [94], VEGF with angiopoietin-1 (Ang-1) [95], and VEGF with keratinocyte
growth factor (KGF) or PDGF [99].
To prolong the release profile of the bioactive factors from the polymeric delivery
systems, the candidate molecules are often encapsulated first within microspheres
that release them more slowly, and then embedded within the scaffolds or hydro-
gels. In order to achieve spatiotemporal control over GFs delivery, an anisotropic
double-layered collagen membrane was developed, comprising a dense layer and
a loose layer, which incorporated basic FGF-loaded chitosan-heparin nanoparticles
[10]. The nanoparticles were prepared by a polyelectrolyte gelation process and, then
were sandwiched between the two layers of the collagen membrane. Different release
amounts of bFGF from the different layers of the membrane induced a significant dif-
ference in cell proliferation, when fibroblastic cells were seeded on the different lay-
ers of membrane. Another system combining protein-loading poly(lactic-co-glycolic
acid) (PLGA) microspheres within collagen and hyaluronic acid gel-like scaffolds
was developed to allow tunable and sustainable protein release kinetics [100]. For
the support of neural stem cell maintenance and proliferation, a composite system
made of hyaluronic acid hydrogel that incorporates PLGA microsphere loaded with
brain-derived neurotrophic factor (BDNF) andVEGFwas developed [101]. The com-
posite appears to be a promising scaffold that provides an ECM mimicking niche
for stem cells and creates a permissive microenvironment for angiogenesis and neu-
ral regeneration. In another attempt, a composite delivery system made of alginate-
poly(L-lysine)-alginate microencapsulated myoblasts incorporating dexamethasone-
loaded PLGA microspheres has proven to be an effective composite release system
[102]. The dexamethosone released from the PLGA generates a potential immune-
privileged local environment to the cells that are microencapsuled and ensheathed.
While biopolymers are versatile in incorporating bioactive factors, bioactive inor-
ganics such as calcium phosphates and glasses have significant limitations in deliv-
ering bioactive factors, because they primarily require high thermal processes in the
shape formulation. In this manner, the bioactive inorganics are generally made into
composites with natural-origin to allow shape formability [13]. However, some of the
valuable physicochemical properties of bioinorganic nanoparticles (mainly calcium
phosphates), such as high electrostatic charge, surface area and roughness, improve
the interaction with and affinity to bioactive factors, allowing suitable matrices for
drug delivering scaffolds [103]. Among the bioactive inorganics, calcium phosphate
cements (CPCs) are among the most attractive group of inorganic biomaterials to be
used as bioactive factor delivery systems. α-tricalcium phosphate-based CPCs can
self-harden and be formulated into microspheres with the help of collagen to deliver
biomolecules. Bovine serum albumin (BSA), used as a model protein, was safely
loaded within the microspheres and then released sustainably over a month [104].
In order to stimulate osteoinduction, BMP-2 was also incorporated within tetracal-
cium phosphate/dicalcium phosphate anhydrous-based CPCs composite with chi-
tosan, which showed significant improvement of osteoblastic cell functions [105].
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The addition of alginate into CPCs-based on calcium carbonate/monocalcium phos-
phate monohydrate prolonged the release of gentamicin, providing a reservoir system
for antibiotic delivery with bone regeneration capability [106].
Currently, one interesting and attractive form of biomaterial scaffolds is the
nanofiber, which is mainly produced by an electrospinning process. A number of
target tissues including skin, nerve, muscle, blood vessel, cartilage and bone, have
utilized the nanofibrous meshes as support for cell culture, for the implementation
of tissue-engineered constructs [107]. Therefore, the development of nanofibrous
scaffolds as drug delivery systems has become an attractive research area. For the
loading of GFs, some common biological proteins such as BSA were used to hold
and stabilize those bioactive factors. For example, NGF was mixed with BSA and,
subsequently, dispersed in the co-solvent of the synthetic copolymer ε-caprolactone-
ethyl ethylene phosphate and, then electrospun into nanofibers [108]. The use of BSA
significantly stabilized the NGF, showing a sustainable release profile over 90 days.
Instead of using BSA, collagen was used with a synthetic polymer, showing simi-
lar effects on epidermal growth factor (EGF) release from the electrospun nanofibers
[109]. Heparin has also been highly effective in stabilizing GFs like EGF and bFGF
within PLA nanofibers [110]. However, these mixture systems are considered rather
case-specific and have limitations in controlling the drug release profiles. An elegant
and general strategy to gain sustainable and controlled release pattern of bioactive
factors from the electrospun nanofibers is the core-shell (or dual-concentric) design.
Some recent studies have highlighted the effectiveness of this core-shell design for
prolonged delivery of GFs. For example, silk fibroin/PCL core-shell nanofibers were
proposed as a potential tissue engineering and drug release system [111].
Tissue regeneration may be enhanced by the delivery of combinations or
sequences of bioactive factors, as single GF delivery has a number of limitations.
Challenges with this combinatorial or sequential delivery of multiple GFs approach
include the selection of proper GF cocktails, understanding their synergies, and rig-
orously controlling their concentrations, gradients and releasing timing (Fig. 31.3)
[13, 112, 113]. Each GF has a specific physiological mechanism of action, and this
drives the selection of a specific release profile. Indeed, if not appropriately chosen,
the delivery of a combination of GFs could lead to inhibitory, as well as stimulatory
responses in bone formation [114–116]. Often, though, the most effective dosage and
release profile is not known, and must be empirically explored.
A work developed by Ripamonti et al. [117] showed, for the first time, that rhTGF-
β1 induces endochondral bone formation in extraskeletal sites of adult baboons.
Furthermore, it was also shown that TGF-β1 and recombinant human osteogenic
protein-1 (OP-1, bone morphogenetic protein-7) synergize in inducing large ossicles
in extraskeletal sites of the primate, as early as 15 days after implantation. A single
application of OP-1, in conjunction with an insoluble collagenous matrix as carrier
(5, 25, and 125 μg/100 mg of carrier matrix) induced bone differentiation in the rec-
tus abdominis of the baboon. This level of tissue induction was raised several-fold by
the simultaneous addition of comparatively low doses of TGF-β1 (0.5, 1.5, and 5 μg),
which by itself induces bone formation in the rectus abdominis at doses of 5 μg/100
mg of carrier matrix. A composite gelatin/β-TCP sponge loaded with BMP-2 and
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FIGURE 31.3 Multiple morphogens can be delivered in sequence or in combination to gain
control of the different phases in healing. The time interval between each growth factor deliv-
ery, the total amount and concentrations, and synergies between factors need to be considered
for the design of these delivery systems. (b) The release of a single growth factor – GF 1.
The area under the curve (a), the peak concentration, and duration of exposure can be used
to control cell behavior. (c) Release of two growth factors (GF 1 and GF 2). The factors can
be delivered with some overlap (region b) or purely in sequence, and the timing of their peak
concentration may also be regulated (c). The choice of overlap depends on their synergistic or
inhibitory effects on osteogenic behavior. Multiple growth factors can also be released using
controlled delivery from biomaterials (GF 3). (d) Rate of release (parameter d) can be defined
based on in vitro experiments that demonstrate cellular response to a desired concentration
and time of exposure for a certain behavioral response. (e) The effective dosage that elicits a
maximum cellular response may have a lower and upper limit defined by a range (parameter
e). A range outside this may cause a lowered or a different response in cellular behaviour. All
these parameters may be similar or different for varying GFs (1, 2, 3, or more). Adapted from
M. Mehta et al. Advanced Drug Delivery Reviews 64 (2012) 1257–1276 [112]. For a color
version of this figure, see the color plate section.
JWST721-c31 JWST721-Neves June 17, 2016 12:21 Printer Name: Trim: 6.125in × 9.25in
U
N
C
O
R
R
E
C
T
E
D
PR
O
O
FS
598 DELIVERY SYSTEMS MADE OF NATURAL-ORIGIN POLYMERS
Wnt1 inducible signaling pathway protein-1 (WISP-1) showed a synergistic ectopic
bone formation in middle-aged mice, suggesting that a scaffold incorporating multi-
ple osteoinductive agents could be effective in age-related bone disease by inducing
new bone formation [118].
Initial approaches to chemically conjugate GFs to collagen matrices/hydrogels
were based on the use of homobiofunctional poly(ethylene glycol) (PEG)-based
crosslinkers containing terminal and primary amine selective succinimidyl groups
[119, 120]. The use of such linkers then expanded to simultaneous crosslinking of
collagen matrices and covalent tethering of GFs. The sustained delivery of tethered
TGF-β2 andVEGF resulted in an enhanced and prolonged response in vivo, compared
to the unmodified GFs. In another attempt, longitudinally oriented poly(L-lactide-
co-D,L-lactide) scaffolds were functionalized with alginate hydrogels incorporating
rrhBMP-2 and rhTGF-β3, these molecules being co-delivered at relatively low doses
(i.e. 200 ng and 20 ng, respectively) and able to promote the repair of a challenging rat
femoral defect [121]. In a similar approach, a combinatorial delivery of BMP-2 with
TGF-β3 within alginate hydrogels has been reported for the transplantation of stem
cells [122]. Previously, the hydrogel was covalently modified with RGD-containing
peptides to stimulate the attachment of rat bone marrow stromal cells (rBMSCs).
When implanted ectopically in mice, the delivery of BMP-2 or TGF-β3 individually
from the alginate hydrogels containing transplanted rBMSCs resulted in negligible
ectopic bone formation. On the other hand, when these GFs were delivered together
from the alginate hydrogels, there was significant bone formation by the transplanted
rBMSCs, suggesting the synergistic role of multiple-delivered GFs.
Based on the anatomophysiology of the bone tissue, the sequential delivery of
angiogenic and osteogenic GFs is a promising strategy for bone regeneration. In a
recent study, a composite biomaterial scaffold made of PLA matrix with alginate
fibers was developed, where VEGF was loaded into the alginate and the BMP-2 was
incorporated into the PLA matrix, aiming at initial VEGF release and, then, BMP-2
release at a much later stage [123]. When the delivery systems were implanted in
mouse segmental femoral defects with hBMSCs, significantly higher bone regener-
ation was observed with respect to the composite scaffolds without GFs. When col-
lagen scaffolds combined with heparin were subcutaneously implanted in rats, the
presence of both FGF2 and VEGF displayed the highest density of blood vessels and
more mature vessels than the cases delivering either of the individual GFs, suggesting
the synergistic roles of both GFs in the series of events involved with blood vessel
formation [203]. A sustained and synergistic effect of a composite system made ofAu: please
correct ref
number
fibrin hydrogel and ionic-albumin microspheres loaded with FGF-2 and granulocyte
colony-stimulating factor (G-CSF) was also demonstrated in a murine critical limb
ischemia model [124]. Another study comprises a cocktail of GFs made of VEGF,
Ang-1, IGF and SDF-1, which were incorporated within composite hydrogels of dex-
tran and PEG diacrylate. The subcutaneous implantation of hydrogels comprising
multiple angiogenic factors dramatically increases the size and number blood ves-
sels compared with any of the GFs used individually [125]. An interesting approach
to stimulate angiogenesis by a sequential delivery of GFs that have different time
dependent roles was recently proposed. A combined system made of micelles in
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Ca-alginate microparticles in PVA hydrogel was developed, where paclitaxel (PTX)
was incorporated into the micelles and VEGF was loaded into the alginate micropar-
ticles [126]. In vitro results demonstrated a short-term release for VEGF and a long-
term release for PTX, aimed at stimulating the proliferation of endothelial cells in
early stages and inhibiting the later proliferation of smooth muscle cells to prevent
the vascular intimal hyperplasia.
The combinatorial delivery of rhBMP-2 and rhIGF-I functionally encapsulated
in either PLGA or silk microspheres, and further incorporated in alginate and silk
scaffolds to form concentration gradients, can significantly affect the osteogenic and
chondrogenic differentiation of hBMSCs, suggesting their usefulness in osteochon-
dral tissue regeneration [127]. Two bone GFs, i.e. BMP-2 and BMP-7, were encapsu-
lated in PLGA and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanocap-
sules which were then incorporated into chitosan-PEO fibrous scaffolds produced by
wet spinning [128]. The sequential release of both BMPs performed better in induc-
ing rBMSCproliferation and osteogenic differentiation (ALP activity) than individual
nanocapsule populations or the populations designed to provide simultaneous release
of the BMPs.
The co-delivery of glial cell line-derived neurotrophic factor (GDNF) and NGF
within collagen nerve conduits was also shown to be effective in early axonal regen-
eration in the peripheral nerve system [129]. Drug release studies point out that
crosslinked collagen tubes sustained the initial release of both neurotrophic factors
more effectively than the non-crosslinked ones (2% vs. 12–16% during 3 days). The
nerve regeneration in a 10 mm rat sciatic nerve gap model, evident as axonal out-
growth and Schwann cell migration, was significantly improved by the sustainable
release and co-delivery of both factors.
Another elaborated system for multiple bioactive factor delivery was reported
to initially suppress inflammatory reactions and, subsequently, to improve repara-
tive and regenerative ability of skin tissue. A system of co-delivery of two anti-
inflammatory drugs, i.e. spantide II and ketoprofen, was designed from nanogels
composed of hydroxypropyl methyl cellulose (HPMC) and bilayered nanoparticles
of PLGA and chitosan [130]. The increase in skin permeation of spantide II and keto-
profen was further responsible for improved response in allergic contact dermatitis
and a psoriatic plaque-like model, suggesting a promising gel for the treatment of
percutaneous delivery of combine drugs into the deeper skin layers for treating skin
inflammatory disorders.
Biomaterials responsive to applied stimuli are another fascinating design of
smart matrices for tissue engineering and carriers for drug delivery. Stimuli can be
given externally, such as light, electrical or magnetic force, or by internal changes
in temperature, pH, and enzymatic reaction. The response of these biomaterials to
stimuli accompanies changes in diverse properties, including surface charge, shape,
and temperature.
Along with pH-responsiveness (described above), thermo-sensitivity is a widely
accepted action of smart biomaterials with stimuli-responsiveness. One of the most
well-known thermo-responsive biopolymers is poly(N-isopropyl acrylamide) (pNI-
PAAm), which presents a typical sol–gel transition at approximately 32◦C [131].
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However, its poor biocompatibility and nondegradability generally require a compos-
ite approach with other biocompatible materials to produce stimuli-responsive and
biologically active composite materials. Moreover, its composites with natural poly-
mers or hydrophilic synthetic polymers generally modulate the transition point near
body temperature as well as allowing the delivery of hydrophilic drugs, enabling bet-
ter applicability in tissue engineering and drug delivery. For example, alginate com-
posite with pNIPAAm was developed as a protein delivery system [132]. The release
of a model protein (i.e. BSA) was highly dependent on the temperature, showing a
higher release rate with temperature decrease. A composite of hyaluronic acid with
pNIPAAm was also exploited to produce thermo-reversible hydrogels for cartilage
tissue engineering [133]. Rabbit chondrocytes were encapsulated into the composite
gel, which also contained TGFβ-3. The thermo-reversible hydrogel construct could
be injected subcutaneously in mice, enhancing the production of cartilage-specific
ECM in the cell-growth factor delivering condition better than those without the
GF. A hyaluronic acid/pluronic thermo-sensitive composite was also developed for
the delivery of cells and GFs in cartilage tissue engineering [134]. Human adipose
derived stem cells and TGF-β1 could be loaded within the composite gel via sol–gel
transition at body temperature allowing in vivo injection. The growth factor release
was moderate, and the in vivo result of the construct loading into a full-thickness
defect of rabbit knee articular cartilage demonstrated the formation of cartilaginous
matrix by the tissue-engineered construct.
31.4.3 Gene Delivery Systems
Originally, the therapeutic application of genes was proposed for the correction of
genetic defects, such as single mutations. Recently, gene therapy has been used to
induce the expression of molecules that are normally involved in the regenerative
response in the tissue of interest [135]. Most of the gene therapy models use vectors
to enhance DNA entry into target cell nuclei and expression of the desired genes. An
ideal vector would possess the following characteristics: avoidance of an immunolog-
ical host response, preferential binding to specific target cells, transduction of divid-
ing and nondividing cells, integration of genes into host cell DNA without disruption
of the normal cell function, expression of genes at an appropriate therapeutic level,
ability to allow external control of protein expression, and easy of production at a
reasonable cost [136]. However, the perfect vector has yet to be developed, because
many of the currently used vectors partially fulfill the above criteria.
The choice of vector for gene therapy depends on the desired duration of protein
function, anatomical location, condition to be treated, and whether an in vivo or ex
vivo approach is favored [137]. The vector systems can be classified into nonviral and
viral vectors. The major advantage of viral vectors is their high frequency of trans-
duction due to the natural tropism of viruses for living cells. The main disadvantages
of viral vectors are their immunogenic potential and, in the case of retroviruses and
certain adeno-associated viruses, the threat of disturbing normal gene function [138].
Nonviral vectors, such as DNA plasmids, lipoplexes, or polyplexes mimic functions
of viral cell entry, but avoid many problems associated with viral vectors, though
generally possess a lower rate of transfection [139]. In addition, physical methods,
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such as electroporation, sonoporation, magnetofection, hydrodynamic methods, and
ballistic methods (the so-called gene gun) have been developed that support nonviral
nucleic acid delivery to cells.
A pioneering study employing natural-derived matrices demonstrated significant
bone regeneration [135,140]. Natural polymers have been applied to a wide range of
gene therapeutics, from nanoparticulates to three-dimensional scaffolds. Nano- and
micro-particles have been applied to oral and intramuscular delivery successfully as
nonviral gene therapy systems. These particulates can bemodified with proteins, such
as KNOB or transferrin, or antibodies/antigens to allow for cell-specific targeting and
enhanced gene transfer. Other studies have demonstrated that nonviral vectors deliv-
ered from natural scaffolds promote tissue formation in a variety of injury models,
such as bone, and the key role that microenvironmental cues play in regulating the
extent of plasmid uptake and expression [141, 142].
Chitosan, a naturally derived polymer from shellfish, has been successfully used in
oral and nasal gene delivery for vaccination [143,144]. In these cases, the mucoadhe-
sive property of chitosan is crucial to the delivery of these particles. For the periodon-
tal tissue regeneration, a similar system has been used, where chitosan/DNA nanopar-
ticles encoding PDGF were incorporated into chitosan/collagen scaffolds [145]. The
plasmid showed a sustained release over 6 weeks and an effective protection by
the chitosan. The in vitro results showed that periodontal ligament cells achieved
high proliferation and were able to form periodontal connective tissue like structure.
To prevent restenosis, stents were coated with chitosan-plasmid DNA nanoparticles
encoding the enhanced green fluorescent protein (GFP), by a spray coating method
[146]. The expression of gene exhibited high level of GFP and an in vivo study con-
firmed gene activity in the region in contact with the stents.
Appropriate modifications made to the natural forms of these polymers can yield
targeted gene delivery to specific cell types, improvement in transfection efficiency as
well as prolonging the residence time once delivered in vivo [147]. Although collagen
gene carrier systems show limited gene transfer success in vivo [148], modified forms
of collagen have shown the capacity for extended release of genes [149]. Ultimately,
the coordinated delivery of multiple genes can be used to aid in multi-cellular tissue
development, with each gene affecting different aspects and stages of tissue growth
and development. Therapeutic genes can also be utilized to enhance incorporation of
a tissue construct once implanted in vivo and enhance growth and assimilation with
neighboring tissues.
31.5 CONCLUDING REMARKS
There is an emergent need in the development of more specific and effective ther-
apeutic agent carriers to help in the regeneration of a plethora of tissues. The ulti-
mate aim of bioactive factor delivery system development is to improve human health
with the fewest possible adverse reactions. While there have been many polymeric
scaffolds and matrices with different forms and compositions developed to load and
deliver bioactive factors, the delivery strategy should be established based on the type
of molecules to deliver and mechanisms to control their release. As most bioactive
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factors such as proteins and genes are water-soluble, natural polymers are more
favored than synthetic ones for this purpose. A core-shell structuring of biomate-
rials (in the cases of particles or fibers) where water-based polymers are placed in
the inner core, may be the most common design principle to secure bioactive factors
during the processing of synthetic drug delivery scaffolds.
While the physical entrapment of bioactive factors within the cargo materials is
one way to gain sustainable and controllable release by the diffusion or erosion pro-
cess, introduction of chemical bonds (such as ionic/covalent bonds or affinity binding)
between the drug molecules with the carrier network can facilitate more stable and
prolonged release. Providing stronger bonds between the scaffolds and the bioactive
factors, while preserving the activity of the bioactive factors has, thus, been exten-
sively researched. Developing affinity-driven bonds, such as utilizing heparin-binding
domains for GF immobilization is considered an effective way of preserving the bio-
logical activity of the factors. The inorganic phase of bone mineral (i.e. hydroxyap-
atite) is also a good example that can be implemented on the surface of polymers to
allow strong and even specific ionic bonds with some bone ECM proteins.
Although the therapeutic actions of the delivered molecules have some impact on
cell behavior, the potential efficacy associated with complex events exerted by the
multiple bioactive factors in vivo in the regenerative processes cannot be simulated
well. The simultaneous or sequential release profile of bioactive factors at proper time
periods and dosages has been achieved by placing or combining different composi-
tions and formulations of carriers and scaffolds. Multilayered scaffolds with each
layer carrying different bioactive factors are one of the methods to gain sequential
release, which primarily showed its effects on the in vitro cellular responses, includ-
ing proliferation and differentiation functions, as well as in vivo tissue repair such
as bone formation, where a concomitant blood vessel formation is achieved by the
release of angiogenic factors.
Development of biomaterials with responsiveness to stimuli including tempera-
ture, pH and ionic strength is another promising strategy to achieve more smart and
multifunctional actions of delivery systems and scaffolds. The pH-responsive poly-
mers like chitosan, alginate, gelatin, polyelectrolytes, and their possible combina-
tions, have revealed applications in the switchable delivery of proteins under pH-
dependent physiological conditions, such as ischemic myocardium (pH 6.8 to 7.4)
and gastric to intestinal change (pH 5.0 to 7.4). Thermo-sensitivity has long been
pursued primarily utilizing pNIPAAm, because of its dramatic sol/gel transition and
swelling/shrinking property near body temperature. Significant studies have proven
the utility of pNIPAAm-based copolymers and composites in temperature-responsive
delivering matrices of proteins and drugs.
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